Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: villani ap. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
Passeron T, Perrot JL, Jullien D, Goujon C, Ruer M, Boyé T, Villani AP, Quiles Tsimaratos N. Passeron T, et al. Among authors: villani ap. JAMA Dermatol. 2024 Feb 1;160(2):199-203. doi: 10.1001/jamadermatol.2023.5051. JAMA Dermatol. 2024. PMID: 38054800
Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis.
Morot J, Del Duca E, Chastagner M, Fernandes M, Estrada Y, Lefevre MA, Kanitakis J, Harou O, Jullien D, Nicolas JF, Krueger JG, Vocanson M, Guttman-Yassky E, Villani AP. Morot J, et al. Among authors: villani ap. JAMA Dermatol. 2023 Aug 1;159(8):820-829. doi: 10.1001/jamadermatol.2023.1651. JAMA Dermatol. 2023. PMID: 37342057
Hidradenitis suppurativa: Impact of the French guidelines on dermatology practices.
Fottorino A, Richard MA, Prouteau C, Balland C, Villani AP, Buche S, Hotz C, Delage M, Nassif A, Cogrel O, Jouan N. Fottorino A, et al. Among authors: villani ap. Ann Dermatol Venereol. 2023 Sep;150(3):227-229. doi: 10.1016/j.annder.2022.09.008. Epub 2023 Mar 7. Ann Dermatol Venereol. 2023. PMID: 36894389 No abstract available.
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.
Ingram JR, Bettoli V, Espy JI, Kokolakis G, Martorell A, Villani AP, Wallinger H, Coak E, Kasparek T, Muscianisi E, Richardson C, Kimball AB. Ingram JR, et al. Among authors: villani ap. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1597-1605. doi: 10.1111/jdv.18163. Epub 2022 May 9. J Eur Acad Dermatol Venereol. 2022. PMID: 35445469 Free PMC article.
Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review.
Chastagner M, Shourik J, Jachiet M, Battistella M, Lefevre G, Gibier JB, Aubert H, Musquer M, Descamps V, Deschamps L, Chosidow O, Ortonne N, Groh M, Bernier M, Jullien D, Chasset F, Staumont-Salle D, Bouaziz JD, Kanitakis J, Villani AP. Chastagner M, et al. Among authors: villani ap. Ann Dermatol Venereol. 2022 Jun;149(2):123-127. doi: 10.1016/j.annder.2021.07.007. Epub 2021 Oct 27. Ann Dermatol Venereol. 2022. PMID: 34716028
67 results